Louis R. Cantilena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Louis R. Cantilena has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Svetlana A. Cherstniakova
3 shared publicationsDaoqin Bi
Division of Clinical Pharmacology and Medical Toxicology, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20819, USA
2 shared publicationsKevin J. Leary
Uniformed Services University of the Health Sciences
2 shared publicationsMichael J. Roy
Division of Military Medicine, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20819, USA
2 shared publicationsAhmed Elkashef
1 shared publication- Bryan Smith
United States Army Medical Materiel Development Activity, 1430 Veterans Drive, Fort Detrick, Maryland 21702, USA
1 shared publication
Latest Publications
- Open Access
- 1 August 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 255
Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
Severe malaria results in over a million deaths every year, most of them in children aged less than five years and living in sub-Saharan Africa. Injectable artesunate (AS) was recommended as initial treatment for severe malaria by WHO in 2006. The Walter Reed Army Institute of Research (WRAIR) has been developing a novel good manufacturing practice (GMP) injection of AS, which was approved by the US FDA for investigational drug use and distribution by the CDC.
- 1 August 2012
- Published by Springer Nature in Malaria Journal
- Vol. 11 (1) , 255
Open AccessPharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
Severe malaria results in over a million deaths every year, most of them in children aged less than five years and living in sub-Saharan Africa. Injectable artesunate (AS) was recommended as initial treatment for severe malaria by WHO in 2006. The Walter Reed Army Institute of Research (WRAIR) has been developing a novel good manufacturing practice (GMP) injection of AS, which was approved by the US FDA for investigational drug use and distribution by the CDC.
- 1 June 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (6) , 870-879
Assessment of the Relative Potency of Fentanyl Buccal Tablet to Intravenous Morphine in Healthy Volunteers Using a Thermally Induced Hyperalgesia Pain Model
This exploratory randomized, double‐blind, placebo‐controlled, 5‐treatment, 5‐period crossover study was conducted using a thermally induced hyperalgesia pain model in 51 healthy volunteers (33 evaluable) to characterize the relative potency of fentanyl buccal tablet (FBT) versus intravenous morphine. Relative potency was assessed using the sum of pain intensity differences over 60 minutes after the application of a 43°C, 46°C, and 49°C painful stimulus following thermally induced hyperalgesia. Relative potency was also assessed by pupil diameter and responses to subjective questionnaires. The relative potency of FBT was 46.2 times that of intravenous morphine (95% confidence interval [CI], 17.6–575.3) based on the 49°C stimulus. The relative potency of FBT based on opiate‐induced miosis was 44.6 (95% CI, 29.7–77.0) at 60 minutes. These results are an initial relative potency assessment and should not be considered guidance for dose‐equivalent switching between agents in clinical practice.
- 1 June 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (6) , 870-879
Assessment of the Relative Potency of Fentanyl Buccal Tablet to Intravenous Morphine in Healthy Volunteers Using a Thermally Induced Hyperalgesia Pain Model
This exploratory randomized, double‐blind, placebo‐controlled, 5‐treatment, 5‐period crossover study was conducted using a thermally induced hyperalgesia pain model in 51 healthy volunteers (33 evaluable) to characterize the relative potency of fentanyl buccal tablet (FBT) versus intravenous morphine. Relative potency was assessed using the sum of pain intensity differences over 60 minutes after the application of a 43°C, 46°C, and 49°C painful stimulus following thermally induced hyperalgesia. Relative potency was also assessed by pupil diameter and responses to subjective questionnaires. The relative potency of FBT was 46.2 times that of intravenous morphine (95% confidence interval [CI], 17.6–575.3) based on the 49°C stimulus. The relative potency of FBT based on opiate‐induced miosis was 44.6 (95% CI, 29.7–77.0) at 60 minutes. These results are an initial relative potency assessment and should not be considered guidance for dose‐equivalent switching between agents in clinical practice.
- 1 November 2007
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 28 (6) , 695-704
Prevalence of abnormal liver-associated enzymes in cocaine experienced adults versus healthy volunteers during Phase 1 clinical trials
- 1 November 2007
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 28 (6) , 695-704
Prevalence of abnormal liver-associated enzymes in cocaine experienced adults versus healthy volunteers during Phase 1 clinical trials
- 1 September 2007
- Published by Elsevier in Journal of Chromatography B
- Vol. 856 (1-2) , 95-99
High performance liquid chromatographic measurement of iothalamate in human serum and urine for evaluation of glomerular filtration rate
- 1 September 2007
- Published by Elsevier in Journal of Chromatography B
- Vol. 856 (1-2) , 95-99
High performance liquid chromatographic measurement of iothalamate in human serum and urine for evaluation of glomerular filtration rate
- Open Access
- 1 January 2006
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 30 (1) , 21-26
Rapid Determination of N,N-Diethyl-m-Toluamide and Permethrin in Human Plasma by Gas Chromatography-Mass Spectrometry and Pyridostigmine Bromide by High-Performance Liquid Chromatography
A rapid and highly sensitive gas chromatography-mass spectrometry (GC-MS) method for simultaneous determination of N,N-diethyl-m-toluamide (DEET) and permethrin with 2H10-phenanthrene (98 atom %) as an internal standard and a separate external standard high-performance liquid chromatography (HPLC) method for pyridostigmine bromide (PB) determination in human plasma were developed and validated. The GC-MS method for DEET and permethrin quantification utilizes a one-step extraction with tert-butylmethylether. The HPLC method for PB quantification involves a solid-phase extraction and UV detection. The range of the analytical method for DEET and permethrin was 1 ng/mL to 100 ng/mL and for PB was 5 ng/mL to 100 ng/mL. Recovery from plasma proved to be more than 80%. The intraday precision ranged from 1.3% to 8% for DEET, from 2.1% to 11.4% for permethrin, and from 3.0% to 4.8% for PB. The interday precision was 3% for DEET, ranged from 5% to 9% for permethrin, and from 5% to 9% for PB. The accuracy for the limit of quantification was 92% ± 8% relative standard deviation (RSD) for DEET, 112% ± 11% RSD for permethrin, and 109% ± 5% RSD for PB. All 3 compounds were stable in human plasma at −80°C for at least 12 months and after 2 freeze-thaw cycles with RSD values ranging from 7.1% (DEET, 80 ng/mL) to 8.1% (DEET, 8 ng/mL), from 2.3% (permethrin, 80 ng/mL) to 11.6 % (permethrin, 8 ng/mL), and from 0.2% (PB, 80 ng/mL) to 3.6% (PB, 8 ng/mL). Both methods were successfully applied to pharmacokinetic/pharmacodynamic studies of combined exposure of DEET (skin application), permethrin (treated uniforms), and PB (30 mg orally three times/day for four doses) in healthy volunteers (n = 81).
- 1 January 2006
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 30 (1) , 21-26
Open AccessRapid Determination of N,N-Diethyl-m-Toluamide and Permethrin in Human Plasma by Gas Chromatography-Mass Spectrometry and Pyridostigmine Bromide by High-Performance Liquid Chromatography
A rapid and highly sensitive gas chromatography-mass spectrometry (GC-MS) method for simultaneous determination of N,N-diethyl-m-toluamide (DEET) and permethrin with 2H10-phenanthrene (98 atom %) as an internal standard and a separate external standard high-performance liquid chromatography (HPLC) method for pyridostigmine bromide (PB) determination in human plasma were developed and validated. The GC-MS method for DEET and permethrin quantification utilizes a one-step extraction with tert-butylmethylether. The HPLC method for PB quantification involves a solid-phase extraction and UV detection. The range of the analytical method for DEET and permethrin was 1 ng/mL to 100 ng/mL and for PB was 5 ng/mL to 100 ng/mL. Recovery from plasma proved to be more than 80%. The intraday precision ranged from 1.3% to 8% for DEET, from 2.1% to 11.4% for permethrin, and from 3.0% to 4.8% for PB. The interday precision was 3% for DEET, ranged from 5% to 9% for permethrin, and from 5% to 9% for PB. The accuracy for the limit of quantification was 92% ± 8% relative standard deviation (RSD) for DEET, 112% ± 11% RSD for permethrin, and 109% ± 5% RSD for PB. All 3 compounds were stable in human plasma at −80°C for at least 12 months and after 2 freeze-thaw cycles with RSD values ranging from 7.1% (DEET, 80 ng/mL) to 8.1% (DEET, 8 ng/mL), from 2.3% (permethrin, 80 ng/mL) to 11.6 % (permethrin, 8 ng/mL), and from 0.2% (PB, 80 ng/mL) to 3.6% (PB, 8 ng/mL). Both methods were successfully applied to pharmacokinetic/pharmacodynamic studies of combined exposure of DEET (skin application), permethrin (treated uniforms), and PB (30 mg orally three times/day for four doses) in healthy volunteers (n = 81).